This EVERSANA white paper examines the rare disease landscape in India, highlighting the growing market, government initiatives, and ongoing challenges in diagnosis, treatment, and access to care. It discusses the National Policy for Rare Diseases 2021, research programs, Centers of Excellence, and funding mechanisms designed to improve patient outcomes, while noting gaps such as underutilized funding, limited epidemiological data, delayed diagnosis, and inadequate clinical trial participation. The paper also identifies opportunities for pharmaceutical companies through partnerships, indication expansion, and collaboration with government agencies, healthcare providers, and patient organizations to improve awareness, access, innovation, and treatment for rare disease patients across India.

Join for free to read